vs
Esperion Therapeutics, Inc.（ESPR）与WESBANCO INC（WSBC）财务数据对比。点击上方公司名可切换其他公司
WESBANCO INC的季度营收约是Esperion Therapeutics, Inc.的1.5倍（$257.2M vs $168.4M），过去两年WESBANCO INC的营收复合增速更高（31.9% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
WesBanco是一家总部位于美国西弗吉尼亚州惠灵的银行控股公司，业务覆盖广泛，目前在西弗吉尼亚州、俄亥俄州、宾夕法尼亚州西部、肯塔基州、马里兰州及印第安纳州南部拥有超过200家营业网点，为当地客户提供多元金融服务。
ESPR vs WSBC — 直观对比
营收规模更大
WSBC
是对方的1.5倍
$168.4M
两年增速更快
WSBC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $257.2M |
| 净利润 | — | $88.6M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 34.5% |
| 营收同比 | 143.7% | — |
| 净利润同比 | — | 54.4% |
| 每股收益（稀释后） | $0.32 | $0.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRWSBC
| Q1 26 | — | $257.2M | ||
| Q4 25 | $168.4M | $265.6M | ||
| Q3 25 | $87.3M | $261.6M | ||
| Q2 25 | $82.4M | $260.7M | ||
| Q1 25 | $65.0M | $193.2M | ||
| Q4 24 | $69.1M | $162.9M | ||
| Q3 24 | $51.6M | $150.8M | ||
| Q2 24 | $73.8M | $147.9M |
净利润ESPRWSBC
| Q1 26 | — | $88.6M | ||
| Q4 25 | — | $91.1M | ||
| Q3 25 | $-31.3M | $83.6M | ||
| Q2 25 | $-12.7M | $57.4M | ||
| Q1 25 | $-40.5M | $-9.0M | ||
| Q4 24 | — | $49.6M | ||
| Q3 24 | $-29.5M | $37.3M | ||
| Q2 24 | $-61.9M | $28.9M |
营业利润率ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 43.2% | ||
| Q3 25 | -11.4% | 39.5% | ||
| Q2 25 | 8.6% | 27.2% | ||
| Q1 25 | -34.0% | -5.0% | ||
| Q4 24 | -6.4% | 38.0% | ||
| Q3 24 | -31.0% | 29.7% | ||
| Q2 24 | 3.5% | 23.7% |
净利率ESPRWSBC
| Q1 26 | — | 34.5% | ||
| Q4 25 | — | 34.3% | ||
| Q3 25 | -35.9% | 31.9% | ||
| Q2 25 | -15.4% | 22.0% | ||
| Q1 25 | -62.2% | -4.7% | ||
| Q4 24 | — | 30.5% | ||
| Q3 24 | -57.2% | 24.7% | ||
| Q2 24 | -83.9% | 19.5% |
每股收益（稀释后）ESPRWSBC
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.32 | $0.97 | ||
| Q3 25 | $-0.16 | $0.84 | ||
| Q2 25 | $-0.06 | $0.57 | ||
| Q1 25 | $-0.21 | $-0.15 | ||
| Q4 24 | $-0.14 | $0.72 | ||
| Q3 24 | $-0.15 | $0.54 | ||
| Q2 24 | $-0.33 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $4.1B |
| 总资产 | $465.9M | $27.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | $956.1M | ||
| Q3 25 | $92.4M | $1.0B | ||
| Q2 25 | $86.1M | $1.2B | ||
| Q1 25 | $114.6M | $1.1B | ||
| Q4 24 | $144.8M | $568.1M | ||
| Q3 24 | $144.7M | $620.9M | ||
| Q2 24 | $189.3M | $486.8M |
股东权益ESPRWSBC
| Q1 26 | — | $4.1B | ||
| Q4 25 | $-302.0M | $4.0B | ||
| Q3 25 | $-451.4M | $4.1B | ||
| Q2 25 | $-433.5M | $3.8B | ||
| Q1 25 | $-426.2M | $3.8B | ||
| Q4 24 | $-388.7M | $2.8B | ||
| Q3 24 | $-370.2M | $2.8B | ||
| Q2 24 | $-344.2M | $2.5B |
总资产ESPRWSBC
| Q1 26 | — | $27.5B | ||
| Q4 25 | $465.9M | $27.7B | ||
| Q3 25 | $364.0M | $27.5B | ||
| Q2 25 | $347.1M | $27.6B | ||
| Q1 25 | $324.0M | $27.4B | ||
| Q4 24 | $343.8M | $18.7B | ||
| Q3 24 | $314.1M | $18.5B | ||
| Q2 24 | $352.3M | $18.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $290.4M | ||
| Q3 25 | $-4.3M | $116.9M | ||
| Q2 25 | $-31.4M | $105.0M | ||
| Q1 25 | $-22.6M | $-26.4M | ||
| Q4 24 | $-35.0M | $211.0M | ||
| Q3 24 | $-35.3M | $60.7M | ||
| Q2 24 | $-7.2M | $18.2M |
自由现金流ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | — | $280.0M | ||
| Q3 25 | — | $114.9M | ||
| Q2 25 | — | $98.3M | ||
| Q1 25 | — | $-30.7M | ||
| Q4 24 | — | $200.7M | ||
| Q3 24 | $-35.5M | $56.9M | ||
| Q2 24 | $-7.3M | $17.3M |
自由现金流率ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | — | 105.4% | ||
| Q3 25 | — | 43.9% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 123.2% | ||
| Q3 24 | -68.7% | 37.7% | ||
| Q2 24 | -9.9% | 11.7% |
资本支出强度ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.9% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 6.3% | ||
| Q3 24 | 0.3% | 2.5% | ||
| Q2 24 | 0.1% | 0.6% |
现金转化率ESPRWSBC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
